search
Back to results

Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients

Primary Purpose

Hypertriglyceridemia

Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
fenofibrate
Sponsored by
Gachon University Gil Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertriglyceridemia focused on measuring adipocytokines, insulin sensitivity, hypertriglyceridemic patients

Eligibility Criteria

25 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • hypertriglyceridemia

Exclusion Criteria:

  • chronic liver disease

Sites / Locations

  • Gil Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

fenofibrate 160 mg, placebo

Arm Description

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
September 2, 2008
Last Updated
September 2, 2008
Sponsor
Gachon University Gil Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00745407
Brief Title
Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients
Study Type
Interventional

2. Study Status

Record Verification Date
September 2008
Overall Recruitment Status
Completed
Study Start Date
January 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
August 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Gachon University Gil Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Fenofibrate increases adiponectin levels, but reduces leptin levels

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertriglyceridemia
Keywords
adipocytokines, insulin sensitivity, hypertriglyceridemic patients

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment

8. Arms, Groups, and Interventions

Arm Title
fenofibrate 160 mg, placebo
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
fenofibrate

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: hypertriglyceridemia Exclusion Criteria: chronic liver disease
Facility Information:
Facility Name
Gil Medical Center
City
Incheon
ZIP/Postal Code
405760
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients

We'll reach out to this number within 24 hrs